{"id":139207,"date":"2026-07-03T16:12:58","date_gmt":"2026-07-03T10:42:58","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=139207"},"modified":"2026-07-03T16:13:00","modified_gmt":"2026-07-03T10:43:00","slug":"astrazeneca-pharma-india-q1-results-2027-preview","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/","title":{"rendered":"Astrazeneca Pharma India Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Astrazeneca Pharma India CMP Rs.8,239. Market cap Rs.20,590 Cr. PE 109.8. 12-month target Rs.8,321-9,392.<\/em><\/p>\n<p>Astrazeneca Pharma India Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with <a href=\"https:\/\/univest.in\/stocks\/astrazen\/astrazeneca-pharma-india-ltd-share-price-today\">Astrazeneca Pharma India<\/a> shares trading at Rs.8,239 against a market capitalisation of Rs.20,590 Cr and a price-to-earnings multiple of 109.8. As a pharmaceuticals and life sciences name on the NSE and BSE, Astrazeneca Pharma India enters the Astrazeneca Pharma India Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.<\/p>\n<p>Quarterly financials for Astrazeneca Pharma India are not yet fully available on Univest&#8217;s data partners for this cycle; investors should track Screener.in and the NSE\/BSE filings directly for the Astrazeneca Pharma India Q1 Results FY27 result date and cross-check any figures before making investment decisions.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=astrazeneca-pharma-india-q1-fy27\"><strong>Get Free Investment Predictions and Astrazeneca Pharma India Research at Univest<\/strong><\/a><\/p>\n<p>Astrazeneca Pharma India (NSE: ASTRAZEN) operates in the pharmaceuticals and life sciences space and is tracked on Univest under its NSE and BSE listings ahead of the Astrazeneca Pharma India Q1 Results FY27 season, forming the base against which the Astrazeneca Pharma India Q1 Results FY27 estimates in this article are built. This Astrazeneca Pharma India Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company&#8217;s own disclosures.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#Astrazeneca_Pharma_India_Q1_FY27_Estimates\" title=\"Astrazeneca Pharma India Q1 FY27 Estimates\">Astrazeneca Pharma India Q1 FY27 Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#Key_Catalysts_to_Watch\" title=\"Key Catalysts to Watch\">Key Catalysts to Watch<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#1_CDMO_Pipeline_Visibility\" title=\"1. CDMO Pipeline Visibility\">1. CDMO Pipeline Visibility<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#2_New_Product_Approvals\" title=\"2. New Product Approvals\">2. New Product Approvals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#3_Capacity_Scale-Up\" title=\"3. Capacity Scale-Up\">3. Capacity Scale-Up<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#Key_Risks_to_the_Astrazeneca_Pharma_India_Q1_Results_FY27_Outlook\" title=\"Key Risks to the Astrazeneca Pharma India Q1 Results FY27 Outlook\">Key Risks to the Astrazeneca Pharma India Q1 Results FY27 Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#Q4_FY26_Performance_Context\" title=\"Q4 FY26 Performance Context\">Q4 FY26 Performance Context<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#Technical_Analysis_Ahead_of_Astrazeneca_Pharma_India_Q1_Results_FY27\" title=\"Technical Analysis Ahead of Astrazeneca Pharma India Q1 Results FY27\">Technical Analysis Ahead of Astrazeneca Pharma India Q1 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#Share_Price_Target_Based_on_the_Astrazeneca_Pharma_India_Q1_Results_FY27_Outlook\" title=\"Share Price Target Based on the Astrazeneca Pharma India Q1 Results FY27 Outlook\">Share Price Target Based on the Astrazeneca Pharma India Q1 Results FY27 Outlook<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#3-6_Month_Target\" title=\"3-6 Month Target\">3-6 Month Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#12-Month_Target\" title=\"12-Month Target\">12-Month Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#FY27-28_Outlook\" title=\"FY27-28 Outlook\">FY27-28 Outlook<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#What_to_Watch_in_the_Astrazeneca_Pharma_India_Q1_Results_FY27_Print\" title=\"What to Watch in the Astrazeneca Pharma India Q1 Results FY27 Print\">What to Watch in the Astrazeneca Pharma India Q1 Results FY27 Print<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#Conclusion_on_Astrazeneca_Pharma_India_Q1_Results_FY27\" title=\"Conclusion on Astrazeneca Pharma India Q1 Results FY27\">Conclusion on Astrazeneca Pharma India Q1 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#FAQs_on_Astrazeneca_Pharma_India_Q1_Results_FY27\" title=\"FAQs on Astrazeneca Pharma India Q1 Results FY27\">FAQs on Astrazeneca Pharma India Q1 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#When_are_Astrazeneca_Pharma_India_Q1_FY27_results_expected\" title=\"When are Astrazeneca Pharma India Q1 FY27 results expected?\">When are Astrazeneca Pharma India Q1 FY27 results expected?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#What_is_the_Astrazeneca_Pharma_India_Q1_FY27_revenue_estimate\" title=\"What is the Astrazeneca Pharma India Q1 FY27 revenue estimate?\">What is the Astrazeneca Pharma India Q1 FY27 revenue estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#What_is_the_Astrazeneca_Pharma_India_share_price_target\" title=\"What is the Astrazeneca Pharma India share price target?\">What is the Astrazeneca Pharma India share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#Is_Astrazeneca_Pharma_India_a_good_buy_before_Q1_FY27_results\" title=\"Is Astrazeneca Pharma India a good buy before Q1 FY27 results?\">Is Astrazeneca Pharma India a good buy before Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#What_should_investors_watch_in_Astrazeneca_Pharma_Indias_Q1_FY27_results\" title=\"What should investors watch in Astrazeneca Pharma India&#8217;s Q1 FY27 results?\">What should investors watch in Astrazeneca Pharma India&#8217;s Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-india-q1-results-2027-preview\/#Where_can_I_track_Astrazeneca_Pharma_India_share_price_live\" title=\"Where can I track Astrazeneca Pharma India share price live?\">Where can I track Astrazeneca Pharma India share price live?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Astrazeneca_Pharma_India_Q1_FY27_Estimates\"><\/span><strong>Astrazeneca Pharma India Q1 FY27 Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse;\">\n<thead>\n<tr style=\"background: #F0F2F5;\">\n<th style=\"padding: 8px; text-align: left; border: 1px solid #DDD;\">Metric<\/th>\n<th style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"padding: 8px; border: 1px solid #DDD;\">CMP<\/td>\n<td style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">Rs.8,239<\/td>\n<\/tr>\n<tr style=\"background: #FFFFFF;\">\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Market Cap<\/td>\n<td style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">Rs.20,590 Cr<\/td>\n<\/tr>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Results Date<\/td>\n<td style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">July-August 2026 (indicative)<\/td>\n<\/tr>\n<tr style=\"background: #FFFFFF;\">\n<td style=\"padding: 8px; border: 1px solid #DDD;\">12-Month Target (Uniresearch Estimate)<\/td>\n<td style=\"padding: 8px; text-align: right; border: 1px solid #DDD;\">Rs.8,321-9,392<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/sebi-registered-investment-advisor-india\"><strong>Univest, a SEBI-Registered Investment Advisor, Tracks Astrazeneca Pharma India Ahead of Q1 FY27 Results<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Catalysts_to_Watch\"><\/span><strong>Key Catalysts to Watch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_CDMO_Pipeline_Visibility\"><\/span><strong>1. CDMO Pipeline Visibility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility is one of the primary variables that analysts are tracking ahead of Astrazeneca Pharma India&#8217;s Q1 FY27 results and FY27 guidance. The market&#8217;s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Astrazeneca Pharma India share price target or faces renewed pressure.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_New_Product_Approvals\"><\/span><strong>2. New Product Approvals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>New product approvals and launches adding to the domestic and export portfolio is one of the primary variables that analysts are tracking ahead of Astrazeneca Pharma India&#8217;s Q1 FY27 results and FY27 guidance. The market&#8217;s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Astrazeneca Pharma India share price target or faces renewed pressure.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Capacity_Scale-Up\"><\/span><strong>3. Capacity Scale-Up<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Operating leverage from scale-up in recently commissioned manufacturing capacity is one of the primary variables that analysts are tracking ahead of Astrazeneca Pharma India&#8217;s Q1 FY27 results and FY27 guidance. The market&#8217;s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Astrazeneca Pharma India share price target or faces renewed pressure.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Astrazeneca Pharma India&#8217;s live price and Q1 FY27 result updates.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Astrazeneca_Pharma_India_Q1_Results_FY27_Outlook\"><\/span><strong>Key Risks to the Astrazeneca Pharma India Q1 Results FY27 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>Pricing pressure in key export markets, particularly the US generics segment.<\/li>\n<li>Regulatory or plant compliance issues affecting supply continuity.<\/li>\n<li>R&amp;D and capacity expansion costs weighing on near-term profitability.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Q4_FY26_Performance_Context\"><\/span><strong>Q4 FY26 Performance Context<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Detailed Q4 FY26 financials for Astrazeneca Pharma India were not available from Univest&#8217;s data partners at the time of writing. Investors should check Screener.in or the company&#8217;s exchange filings for the latest verified numbers before the Q1 FY27 results.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Analysis_Ahead_of_Astrazeneca_Pharma_India_Q1_Results_FY27\"><\/span><strong>Technical Analysis Ahead of Astrazeneca Pharma India Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Astrazeneca Pharma India shares last traded at Rs.8,239. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Share_Price_Target_Based_on_the_Astrazeneca_Pharma_India_Q1_Results_FY27_Outlook\"><\/span><strong>Share Price Target Based on the Astrazeneca Pharma India Q1 Results FY27 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"3-6_Month_Target\"><\/span><strong>3-6 Month Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Over a 3-6 month horizon, the Astrazeneca Pharma India Q1 Results FY27 trailing-growth framework points to a range of Rs.8,082-8,742 for Astrazeneca Pharma India, contingent on the Astrazeneca Pharma India Q1 Results FY27 print matching or beating the trailing growth trend.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12-Month_Target\"><\/span><strong>12-Month Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month target (Uniresearch estimate) tied to this Astrazeneca Pharma India Q1 Results FY27 view for Astrazeneca Pharma India works out to Rs.8,321-9,392, built on the same trailing revenue growth trend and current valuation multiple. Tracking is how Univest research categorises the stock heading into Astrazeneca Pharma India Q1 Results FY27, not a formal Buy or Sell call.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FY27-28_Outlook\"><\/span><strong>FY27-28 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Astrazeneca Pharma India Q1 Results FY27 analysis would put Astrazeneca Pharma India in a Rs.8,783-10,266 range, though this is sensitive to sector-wide demand, cost trends and any change in the company&#8217;s competitive position.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_to_Watch_in_the_Astrazeneca_Pharma_India_Q1_Results_FY27_Print\"><\/span><strong>What to Watch in the Astrazeneca Pharma India Q1 Results FY27 Print<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>Revenue and PAT versus the Astrazeneca Pharma India Q1 Results FY27 estimate range in this preview.<\/li>\n<li>Management commentary on FY27 growth guidance and margin trajectory relevant to the Astrazeneca Pharma India Q1 Results FY27 narrative.<\/li>\n<li>Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility<\/li>\n<li>Pricing pressure in key export markets, particularly the US generics segment<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_on_Astrazeneca_Pharma_India_Q1_Results_FY27\"><\/span><strong>Conclusion on Astrazeneca Pharma India Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Astrazeneca Pharma India enters the Q1 FY27 results season trading at Rs.8,239, with the 12-month Uniresearch target range of Rs.8,321-9,392 reflecting a tracking stance. Investors tracking the Astrazeneca Pharma India Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Astrazeneca_Pharma_India_Q1_Results_FY27\"><\/span><strong>FAQs on Astrazeneca Pharma India Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_are_Astrazeneca_Pharma_India_Q1_FY27_results_expected\"><\/span><strong>When are Astrazeneca Pharma India Q1 FY27 results expected?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. Astrazeneca Pharma India&#8217;s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Astrazeneca_Pharma_India_Q1_FY27_revenue_estimate\"><\/span><strong>What is the Astrazeneca Pharma India Q1 FY27 revenue estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. Detailed quarterly estimates are not available for Astrazeneca Pharma India at this time; check Screener.in or the company&#8217;s exchange filings for verified numbers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Astrazeneca_Pharma_India_share_price_target\"><\/span><strong>What is the Astrazeneca Pharma India share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. The 12-month Uniresearch estimate for Astrazeneca Pharma India share price target is Rs.8,321-9,392, based on trailing growth and current valuation multiples.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Astrazeneca_Pharma_India_a_good_buy_before_Q1_FY27_results\"><\/span><strong>Is Astrazeneca Pharma India a good buy before Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. Astrazeneca Pharma India is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_watch_in_Astrazeneca_Pharma_Indias_Q1_FY27_results\"><\/span><strong>What should investors watch in Astrazeneca Pharma India&#8217;s Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_track_Astrazeneca_Pharma_India_share_price_live\"><\/span><strong>Where can I track Astrazeneca Pharma India share price live?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ans. Astrazeneca Pharma India share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"When are Astrazeneca Pharma India Q1 FY27 results expected?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Astrazeneca Pharma India's Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.\"}},{\"@type\":\"Question\",\"name\":\"What is the Astrazeneca Pharma India Q1 FY27 revenue estimate?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Detailed quarterly estimates are not available for Astrazeneca Pharma India at this time; check Screener.in or the company's exchange filings for verified numbers.\"}},{\"@type\":\"Question\",\"name\":\"What is the Astrazeneca Pharma India share price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The 12-month Uniresearch estimate for Astrazeneca Pharma India share price target is Rs.8,321-9,392, based on trailing growth and current valuation multiples.\"}},{\"@type\":\"Question\",\"name\":\"Is Astrazeneca Pharma India a good buy before Q1 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Astrazeneca Pharma India is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.\"}},{\"@type\":\"Question\",\"name\":\"What should investors watch in Astrazeneca Pharma India's Q1 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility.\"}},{\"@type\":\"Question\",\"name\":\"Where can I track Astrazeneca Pharma India share price live?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Astrazeneca Pharma India share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Astrazeneca Pharma India Q1 Results FY27 preview: revenue and PAT estimates, results date, key catalysts, risks and share price target.<\/p>\n","protected":false},"author":35,"featured_media":139675,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-139207","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1783075384:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_focus_keyword":["Astrazeneca Pharma India Q1"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Astrazeneca Pharma India Q1 FY27 Results Preview"],"rank_math_description":["Astrazeneca Pharma India Q1 Results FY27 preview: revenue estimate, PAT outlook, results date, key catalysts, risks and share price target based on trailing growth analys"],"_thumbnail_id":["139675"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["23359"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/07\/Astrazeneca-Pharma-India-Q1-Results-FY27.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/139207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=139207"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/139207\/revisions"}],"predecessor-version":[{"id":139677,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/139207\/revisions\/139677"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/139675"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=139207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=139207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=139207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}